Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers Edited by Gregg L. Semenza, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved October 13, 2011 (received for review July 23, 2011) Activation of the PI3K and epidermal growth factor receptor (EGFR) pathway is able to drive oncogenesis in multiple human cancers, including head and neck squamous cell carcinoma. Targeted agents such as cetuximab and erlotinib are currently used in patients with head and neck squamous cell carcinoma, but, in this disease, the genomic alterations that cause pathway activation and determine response to pharmacologic inhibition remain ill-defined. Here, we present a detailed dissection of the EGFR/PI3K pathway, composed of sequencing of the core pathway components, and high-resolution genomic copy number assessment. Mutations were found in PIK3CA (6%), but no point mutations were observed in other pathway genes such as PTEN and EGFR. In contrast, we observed frequent copy number alterations of genes in the pathway, including PIK3CA, EGFR, protein tyrosine phosphatase receptor S (PTPRS), and RICTOR. In total, activating genetic pathway alterations were identified in 74% of head and neck tumors. Importantly, intragenic microdeletions of the EGFR phosphatase PTPRS were frequent (26%), identifying this gene as a target of 19p13 loss. PTPRS loss promoted EGFR/PI3K pathway activation, modulated resistance to EGFR inhibition, and strongly determined survival in lung cancer patients with activating EGFR mutations. These findings have important implications for our understanding of head and neck cancer tumorigenesis and for the use of targeted agents for this malignancy. oral cancer | tumor suppressor H ead and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide (1) . As in several other cancers, activation of PI3K and epidermal growth factor receptor (EGFR) signaling HNSCC plays a key role in driving oncogenesis (2-9). The high frequency of receptor tyrosine kinase/PI3K-signaling activation has made this pathway an attractive target for the development of novel therapeutic agents (10) . However, in HNSCC, the nature of the genetic events underlying pathway activation remains ill-defined.
When bound to ligand, EGFR activates the PI3Ks, leading to the phosphorylation of phosphatidylinositol on the 3′-hydroxyl group (11, 12) . The resultant product, phosphatidylinositol-3,4,5-trisphosphate, activates AKT kinase (13, 14) . Specific components of the EGFR/PI3K pathway have been found to be mutated in human cancers, resulting in pathway activation. For example, oncogenic mutations in EGFR, PIK3CA, and PTEN occur commonly in a variety of cancers, such as lung, breast, prostate cancer, and glioblastoma (2, 7, (15) (16) (17) (18) (19) (20) . However, in many cancer types, including HNSCC, the primary genetic causes of pathway activation are poorly understood. A comprehensive genetic analysis would be useful in identifying the driving lesions underlying pathway activation in HNSCC.
Furthermore, agents that target the EGFR/PI3K pathway, such as cetuximab, erlotinib, and PI3K inhibitors, have shown significant promise in patients with head and neck cancers (21, 22) , but responses are heterogeneous and the genetic determinants of response are obscure. This lack of understanding is the primary factor hindering the effective use of these agents. In HNSCC, classical driver mutations of the pathway, such as PTEN and EGFR mutations, are rare, as are mutations in ERBB2-4 and members of the RAS pathway (23) (24) (25) (26) (27) . To resolve this question, we undertook a detailed genomic dissection of the EGFR/PI3K pathway in oral cancer, the most common subsite of HNSCC. Here, we describe the genetic landscape of this pathway in these cancers and identify a frequently altered modulator of sensitivity to EGFR inhibition. These findings have significant impact on our understanding of HNSCC oncogenesis and facilitate the efficacious use of anti-EGFR/PI3K therapy.
Results and Discussion
Copy Number Landscape of the EGFR/PI3K Pathway in HNSCC. The components of the EGFR/PI3K pathway have been well described. The pathway consists of 26 core gene products. To determine whether these genes are genetically altered in HNSCC, we used an integrated genetic strategy consisting of high-resolution global copy number and mutational analysis of EGFR/PI3K pathway genes. We assembled a collection of 31 high-quality oral cavity HNSCC tumors (Table S1 and SI Materials and Methods). Tumor samples with matched normal tissue were collected during routine clinical care with patient consent under an institutional review board-approved protocol and snap-frozen. Single-nucleotide polymorphism fingerprinting was used to ensure that all tumor samples were obtained from unique patients and correctly matched to normal tissue (28) . To determine the copy number landscape of HNSCC, DNA from microdissected tumors was extracted and analyzed using the Agilent 1M Human Comparative Genomic Hybridization (CGH) microarray (aCGH).
Regions of recurrent copy number alteration (CNA) in HNSCC were identified using the RAE method (29) , revealing a number of significant focal amplifications and deletions, as well as gains and losses of 15 chromosomal arms ( Fig. 1A and Table  S2 ). The most frequent CNAs observed were gain of chomosome 3q, which harbors PIK3CA and is amplified in many cancers; loss of chromosome 3p, which harbors FHIT, TGFBR2, and FOXP1 and is frequently lost in epithelial cancers; and loss of chromosome 8p, which harbors NKX3 and DUSP4 (30) (31) (32) (33) . EGFR/PI3K pathway genes within regions of significant copy number gain included PIK3CA (frequency = 45.2%, q = 7.45 × 10
), RIC-TOR (frequency = 38.7%, q = 1.12 × 10 −4 ), and EGFR (frequency = 32.3%, q = 3.42 × 10
−5
). Pathway genes within significant areas of loss included PTPRS (frequency = 26%, q = 3.42 × 10 −5 ), which encodes a transmembrane tyrosine phosphatase (Fig. 1B and Fig. S1 ). CNAs were confirmed by genomic quantitative PCR (qPCR) (Fig. 1C) .
Protein Tyrosine Phosphatase Receptor S (PTPRS) Is Frequently
Deleted in HNSCC. Of particular note, intragenic PTPRS deletion was observed in 26% of samples (8/31) . If broader deletion events in 19p13 including PTPRS are also counted, the frequency of significant PTPRS loss or deletion was 32% (11/31) (Fig. 1B) . To the best of our knowledge, focal somatic alteration of this gene has not been described in human disease. PTPRS has been shown to directly interact with and dephosphorylate EGFR (34, 35) . We observed deletions in this gene that were highly focal, robustly identifying PTPRS as the target of CNA on chromosome 19p13.3, a genomic region frequently lost in several cancers and thought to harbor an as-yet-unidentified tumor suppressor (36) (37) (38) (39) . Interestingly, several unique tumors had similar deletions, suggesting that loss of these regions may be highly selected in HNSCC. Notably, however, one tumor had a deletion at exon 1, a region far removed from the other deletions. It is possible that clustering of copy number loss in the central region of the gene results in more efficient elimination of the transcript. Alternatively, it is also possible that the chromatin state of this region of the gene makes it more susceptible to alteration. Hotspots for DNA alterations are known to be influenced by chromatin structure and features of the neighboring DNA sequence (40, 41) . Our data here suggest that CNAs in these four components of the EGFR/PI3K pathway are important for pathway activation in HNSCC, although we cannot definitively rule out involvement of other genes within the regions of CNA.
Genetic Alteration Within the PI3K Pathway Is Frequent in HNSCC.
To determine whether components of the EGFR/PI3K pathway are altered by somatic point mutations, we sequenced the coding exons of all 26 genes in the same tumors subjected to copy number analysis (SI Materials and Methods and Table S3 ). PIK3CA mutations were observed (6%), but point mutations were not found in other genes of the pathway, including EGFR and PTEN (Fig. S2 and Table S4 ). Our high-resolution aCGH data revealed no EGFRvIII deletions, consistent with some prior data in HNSCC (42) . We integrated the data for mutations and significant CNAs within the EGFR/PI3K pathway genes and categorized the alterations as either pathway-activating or pathway-inactivating ( Fig. 2A and Fig. S2 ). Several patterns were evident from this analysis. First, the significant alterations were all pathway activating, and the total frequency of activating alterations in the EGFR/PI3K pathway was high (74%) in HNSCC. Second, it appears that genomic alterations that can potentially increase PI3K pathway activity were not mutually exclusive in HNSCC. This pattern has been observed in a number of malignancies, including cancers of the breast, endometrium, and colon. For example, PIK3CA and PTEN mutations coexist in all three tumor types and, in many cancers, are the rule rather than the exception (43, 44) . In HNSCC, the coexistence of CNAs and mutations in EGFR/PI3K pathway genes occur because these alterations may synergize to induce PI3K activity in conditions of low ligand availability, or because the alterations are not entirely redundant (43) .
Unsupervised hierarchical clustering of CNAs revealed that there are three subgroups of head and neck tumors defined by copy number cluster: those with minimal, intermediate, and high levels of copy number alteration (Fig. 2B) . Gain and loss of PIK3CA, RICTOR, EGFR, and PTPRS are distributed across all groups, indicating that these CNAs are not solely a function of increasing genomic instability. To verify that tumors harboring these genetic alterations had evidence of downstream pathway activation, we performed immunohistochemistry on these samples using antibodies to phospho-AKT, phospho-PRAS40, and phospho-S6. We found that tumors with EGFR/PI3K pathway gene alterations were functionally activated by the signaling pathway (Fig. 2C) . Both pathway activation and the presence of genetic alteration within the pathway were associated with poorer prognosis in these patients (Fig. 2D) .
PTPRS Loss Promotes EGFR Activation. Particularly intriguing is the high frequency of focal PTPRS deletion. Alterations of PTPRS in cancer are poorly described, and no focal alterations of this gene have been documented. Biochemical experiments have demonstrated that PTPRS directly interacts with EGFR and dephosphorylates and inactivates EGFR and loss of PTPRS enhances EGFR-induced transformation (34, 35) . The microdeletions in PTPRS result in loss of mRNA expression (Fig. 3A) . PTPRS deletions were observed along with PIK3CA or RICTOR alteration, but also occurred in the absence of any other pathway alterations. Importantly, tumors with PTPRS deletion, but no EGFR amplification or mutation, had substantial levels of phospho-EFGR, phospho-AKT, phospho-PRAS40, and phospho-S6, compared with matched normal tissue, indicating pathway activation. (Fig. 3B) . To determine whether PTPRS loss can directly promote EGFR activation in HNSCC cancer cells, we used siRNA to knock down PTPRS in HNSCC cells. Depletion of PTPRS with two independent siRNAs, but not with scrambled siRNA, led to dramatically increased phospho-EGFR, indicating that loss of the phosphatase is sufficient to promote EGFR activation (Fig. 3C) . Consistent with these findings, we observed pathway activation (elevated levels of phospho-EGFR and phospho-AKT) in tumors with PTPRS deletion, but not in tumors lacking PTPRS deletion and EGFR amplification (Fig. 3D) . We then examined an independent dataset of lung adenocarcinomas (45) and found that low PTPRS expression correlated with increased levels of phospho-EGFR (P = 0.027) (Fig. S3) . Combined with our observations above, these data suggest that PTPRS deletion in the absence of EGFR gene alterations can promote EGFR/PI3K pathway activation in HNSCC.
PTPRS Modulates Resistance to EGFR Inhibition. Although anti-EGFR agents such as cetuximab and erlotinib are used in the treatment of HNSCC, responses to therapy are inconsistent, and the molecular determinants of response are still not well defined (22, 46, 47) . Because PTPRS can directly regulate EGFR activity, we sought to determine whether PTPRS loss affects the sensitivity of cancer cells to EGFR inhibition. We performed cell viability assays using the tyrosine kinase inhibitor erlotinib, which clinically has activity in both HNSCC and lung cancer. We found that PTPRS knockdown increased resistance of the EGFR-dependent cell lines HCC827 (EGFR exon 19 deletion) and H3255 (EGFR L858R) to erlotinib treatment (Fig. 4A and Fig. S4) . Similarly, knockdown of PTPRS in HNSCC cell lines sensitive to EGFR inhibition significantly modulated response to erlotinib (Fig. 4B and Fig. S4 ).
Like erlotinib, cetuximab also targets EGFR. We found that PTPRS expression predicted response to cetuximab in HNSCC cell lines. Examination of an expression dataset of cetuximabsensitive and cetuximab-resistant HNSCC cell lines showed that PTPRS expression was significantly lower in resistant cells (P = 6 × 10 −4 ) (Fig. 4C) (48) . Unfortunately, expression datasets from patients with tyrosine kinase inhibitor (TKI)-sensitive and -resistant HNSCC and lung tumors are not currently available for our analysis. However, we analyzed outcomes in a clinical cohort of lung adenocarcinomas with TKI-sensitive EGFR mutations and found that low PTPRS-expressing tumors were associated with markedly poorer outcome (P = 0.03) (Fig. 4D) (31) , demonstrating that PTPRS significantly influences clinical prognosis.
These data demonstrate that components of the EGFR/PI3K pathway are frequently altered at the genetic level in HNSCC. This conclusion is consistent with previous reports examining a few specific candidates (49) and with some immunohistochemical studies (42) . Our data elucidate the landscape of the EGFR/PI3K pathway in HNSCC. Importantly, we observed that intragenic deletion of the EGFR phosphatase PTPRS is one of the most common events in HNSCC, helps promote EGFR/ PI3K pathway activation, and modulates sensitivity to EGFR inhibitors. These findings have important implications for the understanding of HNSCC oncogenesis and for the judicious use of targeted agents in this malignancy.
Materials and Methods
See SI Materials and Methods for a complete description of materials andmethods.
Tumor Samples, aCGH Analysis, and Bioinformatics. HNSCC tumors from the Memorial Sloan-Kettering Cancer Center were obtained after patient consent under an institutional review board-approved protocol. DNA was extracted from microdissected tumors and assessed on the Agilent 1M comparative (48) . Boxplots represent medians and upper/lower quartiles. Groups were compared using a two-tailed t test. (D) Clinical outcome by PTPRS expression in lung adenocarcinomas with TKI-sensitive EGFR mutations. Cases treated at Memorial Sloan-Kettering Cancer Center were categorized as low (below median) or normal PTPRS expressors, and recurrence and survival were calculated using the Kaplan-Meier method and a log-rank test (31) .
